Lv1
40 积分 2024-10-27 加入
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
1个月前
已完结
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
1个月前
已完结
LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
1个月前
已关闭
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
2个月前
已完结
OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function
2个月前
已完结
Macrophages in health and disease
2个月前
已完结
Targeting OX40 by monoclonal antibody PF-04518600 to enhance T cell functions and inhibit tumor growth
2个月前
已关闭
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
3个月前
已完结
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
3个月前
已完结
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
3个月前
已完结
皖公网安备34019202002308
